NEW YORK, N.Y., -- Manhattan Scientifics (OTC BB: MHTX) today issued a letter from the company CEO, Manny Tsoupanarias.
I hope that everyone has enjoyed a wonderful summer and as many of you may have read in our recent press release, our common shares are now quoted on the OTC:BB. We worked very hard to get back to this trading system because it was in the best interests of our company and our shareholders. We will continue to work hard to create shareholder value.
We are currently working with potential customers and partners to validate and commercialize Manhattan Scientifics’ nano-structured metal technology. As we continue to advance and meet our goals of commercializing this technology, we will continue to leverage our core skills in the nano-structuring of metals and advanced process technologies that can be translated into a broad range of products and applications with the possibility of generating near-term revenues for our company.
I would also like to thank all our shareholders for their continued support and patience.
Manny Tsoupanarias, CEO
Manhattan Scientifics, Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.